{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-093066","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2026-08-10T12:35:01+00:00","discovered_at":"2026-08-10T12:40:00.237014+00:00","generated_at":"2026-08-10T12:40:11.717397+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Theravance Q2: YUPELRI collab revenue up 11% to $20.7M; non-GAAP ops income $9.5M; Zymeworks deal on track","bullets":["Net loss $5.9M vs net income $54.8M in Q2 2025 (2025 included $75.1M gain on TRELEGY royalty sale); non-GAAP ops income $9.5M vs loss $4.2M.","YUPELRI US net sales $70.7M (Viatris), up 7% YoY; collaboration revenue $20.7M, up 11% YoY; TRELEGY global net sales ~$1.0B in Q2.","Opex down 35% YoY excl. restructuring/transaction costs; restructuring to cut opex ~60% vs 2025's $111.1M, ~$70M savings in 2H 2026.","Zymeworks acquisition at $17.00/share cash plus CVR (80% of ampreloxetine monetization) expected to close 2H 2026; cash $388M, no debt.","High confidence in $100M Royalty Pharma milestone if FY 2026 TRELEGY net sales reach ~$3.5B; FY 2025 $3.9B triggered $50M paid Feb 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-093066","json":"https://secwatch.observer/filing/0001104659-26-093066.json","markdown":"https://secwatch.observer/filing/0001104659-26-093066.md","text":"https://secwatch.observer/filing/0001104659-26-093066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926093066/0001104659-26-093066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926093066/tm2622638d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T12:40:11.717397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}